GeoVax Labs (GOVX) 10-Q 10 Aug 20 2020 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Aug. 10, 2020
Document Information [Line Items]
Entity Registrant Name	GeoVax Labs, Inc.
Entity Central Index Key	0000832489
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		15,436,913
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Jun. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
ASSETS
Cash and cash equivalents	$ 710,682	$ 283,341
Grant funds and other receivables	187,163	68,603
Prepaid expenses and other current assets	40,470	95,320
Total current assets	938,315	447,264
Property and equipment, net (Note 5)	8,618	10,606
Deposits	11,010	11,010
Total assets	957,943	468,880
Current liabilities:
Accounts payable	91,416	152,653
Accrued expenses (Note 6)	2,076,359	1,851,040
Current portion of notes payable	182,379	12,500
Carrying value at June 30, 2020	435,711
Total current liabilities	2,785,865	2,016,193
Note payable, net of current portion	21,699	27,243
Total liabilities	2,807,564	2,043,436
Commitments (Note 9)
Stockholders’ equity (deficiency):
Preferred Stock, $.01 par value (Note 10): Authorized shares – 10,000,000 Issued and outstanding shares – 400 and 2,486 June 30, 2020 and December 31, 2019, respectively	376,095	1,932,433
Common stock, $.001 par value: Authorized shares – 600,000,000 Issued and outstanding shares – 13,834,075 and 299,835 at June 30, 2020 and December 31, 2019, respectively	13,834	300
Additional paid-in capital	41,658,861	39,340,224
Accumulated deficit	(43,898,411)	(42,847,513)
Total stockholders’ equity (deficiency)	(1,849,621)	(1,574,556)
Total liabilities and stockholders’ equity (deficiency)	$ 957,943	$ 468,880

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	400	2,486
Preferred stock, shares outstanding (in shares)	400	2,486
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	600,000,000	600,000,000
Common stock, shares issued (in shares)	13,834,075	299,835
Common stock, shares outstanding (in shares)	13,834,075	299,835

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Grant and collaboration revenue	$ 440,602	$ 209,941	$ 1,156,579	$ 574,173
Operating expenses:
Research and development	461,421	451,227	1,270,357	1,006,945
General and administrative	427,292	412,650	929,637	922,714
Total operating expenses	888,713	863,877	2,199,994	1,929,659
Loss from operations	(448,111)	(653,936)	(1,043,415)	(1,355,486)
Other income (expense):
Interest income	60	881	812	2,105
Interest expense	(7,153)	(1,093)	(8,295)	(2,221)
Total other income (expense)	(7,093)	(212)	(7,483)	(116)
Net loss	$ (455,204)	$ (654,148)	$ (1,050,898)	$ (1,355,602)
Basic and diluted:
Net loss per common share (in dollars per share)	$ (0.03)	$ (1,994.35)	$ (0.11)	$ (4,706.95)
Weighted average shares outstanding (in shares)	13,823,452	328	9,255,497	288

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficiency) (Unaudited) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2018	3,450	219
Balance at Dec. 31, 2018	$ 1,971,333		$ 37,483,204	$ (40,476,884)	$ (1,022,347)
Sale of convertible preferred stock for cash and cancellation of note payable (in shares)	500
Sale of convertible preferred stock for cash and cancellation of note payable	$ 404,250		85,750		490,000
Conversion of preferred stock to common stock (in shares)	(767)	59
Conversion of preferred stock to common stock	$ (303,475)		303,475
Net loss				(701,454)	(701,454)
Balance (in shares) at Mar. 31, 2019	3,183	278
Balance at Mar. 31, 2019	$ 2,072,108		37,899,081	(41,178,338)	(1,207,149)
Stock option expense			26,652		26,652
Balance (in shares) at Dec. 31, 2018	3,450	219
Balance at Dec. 31, 2018	$ 1,971,333		37,483,204	(40,476,884)	(1,022,347)
Net loss					(1,355,602)
Balance (in shares) at Jun. 30, 2019	3,402	407
Balance at Jun. 30, 2019	$ 2,337,867		38,165,986	(41,832,486)	(1,328,633)
Balance (in shares) at Dec. 31, 2018	3,450	219
Balance at Dec. 31, 2018	$ 1,971,333		37,483,204	(40,476,884)	(1,022,347)
Net loss
Balance (in shares) at Mar. 31, 2020	400	13,791,598
Balance at Mar. 31, 2020	$ 376,095	$ 13,792	41,189,070	(43,443,207)	(1,864,250)
Balance (in shares) at Mar. 31, 2019	3,183	278
Balance at Mar. 31, 2019	$ 2,072,108		37,899,081	(41,178,338)	(1,207,149)
Sale of convertible preferred stock for cash and cancellation of note payable (in shares)	500
Sale of convertible preferred stock for cash and cancellation of note payable	$ 438,700		61,300		500,000
Conversion of preferred stock to common stock (in shares)	(281)	127
Conversion of preferred stock to common stock	$ (172,941)		172,941
Common stock issued for services (in shares)		2
Common stock issued for services			6,000		6,000
Net loss				(654,148)	(654,148)
Balance (in shares) at Jun. 30, 2019	3,402	407
Balance at Jun. 30, 2019	$ 2,337,867		38,165,986	(41,832,486)	(1,328,633)
Stock option expense			26,664		26,664
Balance (in shares) at Dec. 31, 2019	2,486	299,835
Balance at Dec. 31, 2019	$ 1,932,433	$ 300	39,340,224	(42,847,513)	(1,574,556)
Sale of convertible preferred stock for cash and cancellation of note payable (in shares)	300
Sale of convertible preferred stock for cash and cancellation of note payable	$ 300,000				300,000
Conversion of preferred stock to common stock (in shares)	(2,386)	13,481,349
Conversion of preferred stock to common stock	$ (1,856,338)	$ 13,481	1,842,857
Common stock issued for services (in shares)		10,417
Common stock issued for services		$ 11	5,989		6,000
Share rounding after reverse split (in shares)		3
Share rounding after reverse split (in shares)		(3)
Net loss				(595,694)	(595,694)
Balance (in shares) at Mar. 31, 2020	400	13,791,598
Balance at Mar. 31, 2020	$ 376,095	$ 13,792	41,189,070	(43,443,207)	(1,864,250)
Balance (in shares) at Dec. 31, 2019	2,486	299,835
Balance at Dec. 31, 2019	$ 1,932,433	$ 300	39,340,224	(42,847,513)	$ (1,574,556)
Common stock issued for services (in shares)					52,894
Net loss					$ (1,050,898)
Balance (in shares) at Jun. 30, 2020	400	13,834,075
Balance at Jun. 30, 2020	$ 376,095	$ 13,834	41,658,861	(43,898,411)	(1,849,621)
Balance (in shares) at Mar. 31, 2020	400	13,791,598
Balance at Mar. 31, 2020	$ 376,095	$ 13,792	41,189,070	(43,443,207)	(1,864,250)
Common stock issued for services (in shares)		42,477
Common stock issued for services		$ 42	11,958		12,000
Net loss				(455,204)	(455,204)
Warrants issued in bridge financing			457,833		457,833
Balance (in shares) at Jun. 30, 2020	400	13,834,075
Balance at Jun. 30, 2020	$ 376,095	$ 13,834	$ 41,658,861	$ (43,898,411)	$ (1,849,621)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash flows from operating activities:
Net loss	$ (1,050,898)	$ (1,355,602)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	7,033	3,795
Stock-based compensation expense	18,000	258,396
Changes in assets and liabilities:
Grant funds and other receivables	(118,560)	57,568
Prepaid expenses and other current assets	54,850	(30)
Accounts payable and accrued expenses	164,082	262,064
Total adjustments	125,405	581,793
Net cash used in operating activities	(925,493)	(773,809)
Cash flows from investing activities:
Purchase of property and equipment		(4,272)
Net cash used in investing activities		(4,272)
Cash flows from financing activities:
Net proceeds from sale of preferred stock	300,000	740,000
Net proceeds from issuance of note payable	170,200
Net proceeds from bridge financing	888,500
Principal repayment of note payable	(5,866)	(5,209)
Net cash provided by financing activities	1,352,834	734,791
Net increase (decrease) in cash and cash equivalents	427,341	(43,290)
Cash and cash equivalents at beginning of period	283,341	259,701
Cash and cash equivalents at end of period	$ 710,682	$ 216,411

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Conversion of Series C Preferred Stock Into Series F Preferred Stock [Member]
Convertible preferred stock (in shares)	1,686	1,563
Conversion of Series E Preferred Stock Into Series F Preferred Stock [Member]
Convertible preferred stock (in shares)	9,393,937	1,200
Conversion of Series C and Series E Preferred Stock Into Series F Preferred Stock [Member]
Conversion of stock, shares issued (in shares)		2,763
Series G Convertible Preferred Stock Issued in Exchange for Cancellation of Term notes Payable [Member]
Convertible preferred stock (in shares)		250
Convertible note, value		$ 250,000
Conversion of Series C Preferred Stock Into Common Stock [Member]
Convertible preferred stock (in shares)		587
Conversion of stock, shares issued (in shares)		39
Conversion of Series F Preferred Stock Into Common Stock [Member]
Convertible preferred stock (in shares)		461
Conversion of stock, shares issued (in shares)		147
Conversion of Series I Preferred Stock Into Common Stock [Member]
Convertible preferred stock (in shares)	700
Conversion of stock, shares issued (in shares)	4,087,412

Note 1 - Description of Busines

Note 1 - Description of Business	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Nature of Operations [Text Block]	1. GeoVax Labs, Inc. (“GeoVax” or the “Company”), is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancers using a novel patented Modified Vaccinia Ankara (MVA) Virus-Like Particle (VLP) vaccine platform (GV-MVA-VLP TM Our current development programs are focused on preventive vaccines against novel coronavirus (COVID- 19 Our corporate strategy is to improve the health of patients worldwide by advancing our vaccine platform, using its unique capabilities to design and develop an array of products addressing unmet medical needs in the areas of infectious diseases and oncology. We intend to advance products through to human clinical testing, and to seek partnership or licensing arrangements for commercialization. We also leverage third Certain of our vaccine development activities have been, and continue to be, financially supported by the U.S. government. This support has been both in the form of research grants and contracts awarded directly to us, as well as indirect support for the conduct of preclinical animal studies and human clinical trials. We operate in a highly regulated and competitive environment. The manufacturing and marketing of pharmaceutical products require approval from, and are subject to, ongoing oversight by the Food and Drug Administration (FDA) in the United States, by the European Medicines Agency (EMA) in the European Union, and by comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, may one GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in the metropolitan Atlanta, Georgia area.

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Basis of Accounting [Text Block]	2. The accompanying condensed consolidated financial statements at June 30, 2020 three six June 30, 2020 2019 not 10 December 31, 2019. not As described in Note 10, April 30, 2019, one five hundred January 21, 2020, one two thousand Our financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve We believe that our existing cash resources together with our government and collaborative funding commitments, will be sufficient to continue our planned operations into the fourth 2020. not may not

Note 3 - Significant Accounting

Note 3 - Significant Accounting Policies and Recent Accounting Pronouncements	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Significant Accounting Policies [Text Block]	3. We disclosed in Note 2 10 December 31, 2019 no 10 There have been no six June 30, 2020, 10 December 31, 2019,

Note 4 - Basic and Diluted Loss

Note 4 - Basic and Diluted Loss Per Common Share	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Earnings Per Share [Text Block]	4. Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents consist of common shares issuable upon conversion of convertible preferred stock, and upon exercise of stock options and stock purchase warrants. All common share equivalents are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. The weighted average number of common share equivalents which were excluded from the computation of diluted loss per share, totaled 1,340,187 1,103,815 three six June 30, 2020, 188 176 three six June 30, 2019, 10 June 30, 2020

Note 5 - Property and Equipment

Note 5 - Property and Equipment	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	5. Property and equipment as shown on the accompanying Condensed Consolidated Balance Sheets is composed of the following as of June 30, 2020 December 31, 2019: June 30, 2020 December 31, 2019 Laboratory equipment $ 534,577 $ 534,577 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 11,736 11,736 Total property and equipment 661,918 661,918 Accumulated depreciation and amortization (653,300 ) (651,312 ) Property and equipment, net $ 8,618 $ 10,606

Note 6 - Accrued Expenses

Note 6 - Accrued Expenses	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	6. Accrued expenses as shown on the accompanying Condensed Consolidated Balance Sheets are composed of the following as of June 30, 2020 December 31, 2019: June 30, 2020 December 31, 2019 Accrued payroll $ 1,508,903 $ 1,323,483 Accrued directors' fees 463,170 409,219 Other accrued expenses 104,286 118,338 Total accrued expenses $ 2,076,359 $ 1,851,040

Note 7 - Notes Payable

Note 7 - Notes Payable	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Debt Disclosure [Text Block]	7. GRA Note On February 28, 2018, five $50,000. 5%, $6,013 2020. $12,487 2021, $13,126 2022, $2,252 2023. three six June 30, 2020 $448 $933, $586 $1,207, 2019. CARES Act Paycheck Protection Program Loan On April 17, 2020, $170,200 one April 17, 2022. No 180 November 17, 2020, $9,578.16 may $345 three June 30, 2020.

Note 8 - Bridge Financing - Con

Note 8 - Bridge Financing - Convertible Debentures	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Short-term Debt [Text Block]	8. Bridge Financing – Convertible Debentures On June 26 2020, two $1,050,000 5% $1,200,000; “June 2020 2,400,000 $0.50 The Convertible Debentures mature in twelve 5% six $0.50 may may first 90 91 180, may 110% 181 365, may 120% The Convertible Debentures will convert into common stock upon our consummation of a public offering of common stock with gross proceeds of $6,000,000 $0.50 80% We recorded a total of $769,334 $457,834 $161,501 $150,000 $5,703 three June 30, 2020, $5,045 $658 The following table summarizes the carrying value of the Convertible Debentures as of June 30, 2020: Principal value $ 1,200,000 Debt discount (769,334 ) Net original carrying value 430,666 Amortization of debt discount 5,045 Carrying value at June 30, 2020 $ 435,711

Note 9 - Commitments

Note 9 - Commitments	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Commitments Disclosure [Text Block]	9. Lease Agreement We lease approximately 8,400 December 31, 2022. three six June 30, 2020 $41,539 $83,078, $40,316 $80,633, 2019. $83,078 2020, $171,213 2021 $176,356 2022, may ninety Other Commitments In the normal course of business, we enter into various firm purchase commitments related to production and testing of our vaccine, conduct of research studies, and other activities. As of June 30, 2020, $400,834 $338,334 2020 $62,500 2021.

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Preferred Stock [Text Block]	10. Preferred Stock Summary 10,000,000 $.01 may one June 30, 2020 December 31, 2019. $1,000 six June 30, 2020 June 30, 2020 December 31, 2019 Carrying Carrying Shares Value Shares Value Series B Convertible Preferred Stock 100 $ 76,095 100 $ 76,095 Series H Convertible Preferred Stock - - 1,686 1,156,338 Series I Convertible Preferred Stock - - 700 700,000 Series J Convertible Preferred Stock 300 300,000 - - Total 400 $ 376,095 2,486 $ 1,932,433 Series B Preferred Stock – no not June 30, 2020, 100 $350,000 no six June 30, 2020. Series H Preferred Stock – no not first 2020, 1,686 9,393,937 June 30, 2020, no Series I Preferred Stock – no not March 2020, 700 4,087,412 June 30, 2020, no Series J Preferred Stock – January 24, 2020, 300 $300,000. no not $2.00 80% ten may, June 2020 June 2020 ( 8 $0.50 80% ten six June 30, 2020, no 300 June 30, 2020. Common Stock Reverse Stock Split – January 3, 2020, January 21, 2020, one two thousand As discussed under “Preferred Stock” above, during the first 2020, 13,481,349 During the six June 30, 2020, 52,894 Stock Options During the six June 30, 2020, no April 2019 January 2020, June 30, 2020 June 19, 2020, 2020 “2020 5,000,000 2020 No 2020 six June 30, 2020. Stock Purchase Warrants The following table summarizes our stock purchase warrants outstanding as of June 30, 2020: Expiration Date Exercise Price Number of Warrants Series G Warrants September 2021 $ 0.50 48 Series H Warrants December 2021 0.50 217,392 Series I Warrants Aug-Dec 2024 0.50 1,500,000 June 2020 Warrants June 2025 0.50 2,400,000 All of the outstanding warrants contain anti-dilution and price adjustment provisions, which may, June 2020 no The Series H Warrants have an additional price adjustment provision requiring a similar adjustment to the exercise price and number of warrants following a reverse stock split of our common stock. The Series G Warrants were originally issued for the purchase of up to 47,169,812 $0.02544 April 2019 January 2020, 48 $25,440 June 2020 June 2020, 48 $0.50 The Series H Warrants were originally issued for the purchase of up to 10,000,000 $0.025 April 2019 January 2020, 217,392 $1.15 June 2020 June 2020, 217,392 $0.50 The Series I Warrants were originally issued for the purchase of up to 33,333,332 $0.015 April 2019 January 2020, 50 $15,000 June 2020 June 2020, 1,500,000 $0.50 The June 2020 June 26, 2020 7. Stock-Based Compensation Expense As discussed above, as a result of the reverse stock splits enacted in April 2019 January 2020, June 30, 2020 no three six June 30, 2020; no June 30, 2020. $26,664 $53,316 three six June 30, 2019, During the three six June 30, 2020 $12,000 $18,000, $78,509 $205,080, 2019,

Note 11 - Income Taxes

Note 11 - Income Taxes	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Income Tax Disclosure [Text Block]	11. Because of our historically significant net operating losses, we have not 382

Note 12 - Grants and Collaborat

Note 12 - Grants and Collaboration Revenue	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Government Grants and Contracts [Text Block]	12. We receive payments from government entities under our grants from the National Institute of Allergy and Infectious Diseases (NIAID) and from the U.S. Department of Defense in support of our vaccine research and development efforts. We record revenue associated with government grants as the reimbursable costs are incurred. During the three six June 30, 2020, $301,493 $955,514, $184,938 $539,257, 2019. June 30, 2020, $650,051 September 2021. During the three six June 30, 2020, $139,109 $201,065, third $25,003 $34,916, 2019.

Note 13 - Subsequent Events

Note 13 - Subsequent Events	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	13. During July 2020, 300 854,458 July 2020, 1,091,128 738,048

Note 5 - Property and Equipme_2

Note 5 - Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Property, Plant and Equipment [Table Text Block]	June 30, 2020 December 31, 2019 Laboratory equipment $ 534,577 $ 534,577 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 11,736 11,736 Total property and equipment 661,918 661,918 Accumulated depreciation and amortization (653,300 ) (651,312 ) Property and equipment, net $ 8,618 $ 10,606

Note 6 - Accrued Expenses (Tabl

Note 6 - Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	June 30, 2020 December 31, 2019 Accrued payroll $ 1,508,903 $ 1,323,483 Accrued directors' fees 463,170 409,219 Other accrued expenses 104,286 118,338 Total accrued expenses $ 2,076,359 $ 1,851,040

Note 8 - Bridge Financing - C_2

Note 8 - Bridge Financing - Convertible Debentures (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Convertible Debt [Table Text Block]	Principal value $ 1,200,000 Debt discount (769,334 ) Net original carrying value 430,666 Amortization of debt discount 5,045 Carrying value at June 30, 2020 $ 435,711

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Schedule of Preferred Stock [Table Text Block]	June 30, 2020 December 31, 2019 Carrying Carrying Shares Value Shares Value Series B Convertible Preferred Stock 100 $ 76,095 100 $ 76,095 Series H Convertible Preferred Stock - - 1,686 1,156,338 Series I Convertible Preferred Stock - - 700 700,000 Series J Convertible Preferred Stock 300 300,000 - - Total 400 $ 376,095 2,486 $ 1,932,433
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Expiration Date Exercise Price Number of Warrants Series G Warrants September 2021 $ 0.50 48 Series H Warrants December 2021 0.50 217,392 Series I Warrants Aug-Dec 2024 0.50 1,500,000 June 2020 Warrants June 2025 0.50 2,400,000

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation (Details Textual)	Jan. 21, 2020	Apr. 30, 2019
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	2,000	500

Note 4 - Basic and Diluted Lo_2

Note 4 - Basic and Diluted Loss Per Common Share (Details Textual) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	1,340,187	188	1,103,815	176

Note 5 - Property and Equipme_3

Note 5 - Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Property and equipment, gross	$ 661,918	$ 661,918
Accumulated depreciation and amortization	(653,300)	(651,312)
Property and equipment, net	8,618	10,606
Laboratory Equipment [Member]
Property and equipment, gross	534,577	534,577
Leasehold Improvements [Member]
Property and equipment, gross	115,605	115,605
Other Furniture Fixtures And Equipment [Member]
Property and equipment, gross	$ 11,736	$ 11,736

Note 6 - Accrued Expenses - Sch

Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Accrued payroll	$ 1,508,903	$ 1,323,483
Accrued directors’ fees	463,170	409,219
Other accrued expenses	104,286	118,338
Total accrued expenses	$ 2,076,359	$ 1,851,040

Note 7 - Notes Payable (Details

Note 7 - Notes Payable (Details Textual) - USD ($)	Apr. 17, 2020	Feb. 28, 2018	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Proceeds from Notes Payable, Total					$ 170,200
Paycheck Protection Program CARES Act [Member]
Proceeds from Notes Payable, Total	$ 170,200
Debt Instrument, Periodic Payment, Total	$ 9,578.16
Interest Payable			$ 345		345
Senior Notes [Member]
Proceeds from Notes Payable, Total		$ 50,000
Debt Instrument, Interest Rate, Stated Percentage		5.00%
Long-Term Debt, Maturity, Remainder of Fiscal Year			6,013		6,013
Long-Term Debt, Maturity, Year One			12,487		12,487
Long-Term Debt, Maturity, Year Two			13,126		13,126
Long-Term Debt, Maturity, Year Three			2,252		2,252
Interest Expense, Debt, Total			$ 448	$ 586	$ 933	$ 1,207

Note 8 - Bridge Financing - C_3

Note 8 - Bridge Financing - Convertible Debentures (Details Textual)	Jun. 26, 2020USD ($)$ / sharesshares	Jun. 30, 2020USD ($)$ / shares	Jun. 30, 2020USD ($)$ / shares
Convertible Debentures [Member]
Debt Instrument, Unamortized Discount, Total	$ 769,334
Interest Expense, Debt, Total		$ 5,703
Amortization of Debt Discount (Premium)		5,045
Interest Payable		$ 658	$ 658
June 2020 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares	2,400,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 0.50	$ 0.50	$ 0.50
Warrants and Rights Outstanding	$ 457,834
Convertible Debentures [Member]
Number of Institutional Investors	2
Proceeds from Convertible Debt, Gross	$ 1,050,000
Debt Instrument, Interest Rate, Stated Percentage	5.00%
Debt Instrument, Face Amount	$ 1,200,000	$ 1,200,000	$ 1,200,000
Debt Instrument, Term (Month)	1 year
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares	$ 0.50
Gross Proceeds from Issuance of Common Stock, Public Offering	$ 6,000,000
Percentage of Offering Price	80.00%
Debt Instrument, Unamortized Discount, Total		$ 769,334	769,334
Payments of Debt Issuance Costs	$ 161,501
Debt Conversion, Original Debt Discount	$ 150,000
Amortization of Debt Discount (Premium)			$ 5,045
Convertible Debentures [Member] | Debt Instrument, Redemption, Period One [Member]
Debt Instrument, Redemption Price, Percentage	110.00%
Convertible Debentures [Member] | Debt Instrument, Redemption, Period Two [Member]
Debt Instrument, Redemption Price, Percentage	120.00%

Note 8 - Bridge Financing - C_4

Note 8 - Bridge Financing - Convertible Debentures - Carrying Value of the Convertible Debentures (Details) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 26, 2020	Dec. 31, 2019
Carrying value at June 30, 2020	$ 435,711
Convertible Debentures [Member]
Principal value	1,200,000	$ 1,200,000
Debt discount	(769,334)
Net original carrying value	430,666
Amortization of debt discount	5,045
Carrying value at June 30, 2020	$ 435,711

Note 9 - Commitments (Details T

Note 9 - Commitments (Details Textual)	3 Months Ended		6 Months Ended
	Jun. 30, 2020USD ($)ft²	Jun. 30, 2019USD ($)	Jun. 30, 2020USD ($)ft²	Jun. 30, 2019USD ($)
Area of Real Estate Property (Square Foot) | ft²	8,400		8,400
Operating Leases, Rent Expense, Total	$ 41,539	$ 40,316	$ 83,078	$ 80,633
Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year	83,078		83,078
Lessee, Operating Lease, Liability, to be Paid, Year One	171,213		171,213
Lessee, Operating Lease, Liability, to be Paid, Year Two	176,356		176,356
Unrecorded Unconditional Purchase Obligation, Total	400,834		400,834
Purchase Obligation, to be Paid, Remainder of Fiscal Year	338,334		338,334
Purchase Obligation, to be Paid, Year One	$ 62,500		$ 62,500

Note 10 - Stockholders' Equit_2

Note 10 - Stockholders' Equity (Details Textual)	Jan. 24, 2020USD ($)$ / sharesshares	Jan. 21, 2020	Apr. 30, 2019	Jun. 30, 2020USD ($)$ / sharesshares	Mar. 31, 2020shares	Jun. 30, 2019USD ($)	Jun. 30, 2020USD ($)$ / sharesshares	Jun. 30, 2019USD ($)	Jun. 20, 2020$ / sharesshares	Jan. 31, 2020$ / sharesshares	Dec. 31, 2019$ / sharesshares
Preferred Stock, Shares Authorized (in shares)				10,000,000			10,000,000				10,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares				$ 0.01			$ 0.01				$ 0.01
Preferred Stock, Shares Outstanding, Ending Balance (in shares)				400			400				2,486
Stock Issued During Period, Shares, Issued for Services (in shares)							52,894
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $				$ 0			$ 0
Stock Issued During Period, Value Expensed During the Period, Issued for Services | $				12,000		$ 78,509	18,000	$ 205,080
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expense | $				$ 0		$ 26,664	$ 0	$ 53,316
Series G Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)									48	48
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares				$ 0.50			$ 0.50		$ 0.50	$ 25,440
Series H Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)									217,392	217,392
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares				0.50			0.50		$ 0.50	$ 1.15
Series I Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)									1,500,000	50
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares				$ 0.50			$ 0.50		$ 0.50	$ 15,000
Stock Incentive Plan 2020 [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)				5,000,000			5,000,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		2,000	500
Reverse Stock Split [Member] | Series G Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				47,169,812			47,169,812
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares				$ 0.02544			$ 0.02544
Reverse Stock Split [Member] | Series H Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				10,000,000			10,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares				$ 0.025			$ 0.025
Reverse Stock Split [Member] | Series I Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				33,333,332			33,333,332
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares				$ 0.015			$ 0.015
Conversion of Series H Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)					1,686
Conversion of Stock, Shares Issued (in shares)					9,393,937
Conversion of Series I Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)					700		700
Conversion of Stock, Shares Issued (in shares)					4,087,412		4,087,412
Conversion of Series H and Series I Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Issued (in shares)					13,481,349
Series B Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares				$ 1,000			$ 1,000				$ 1,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)				100			100				100
Convertible Preferred Stock, Conversion Price1 (in dollars per share) | $ / shares				$ 350,000			$ 350,000
Series H Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)				0			0				1,686
Series I Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)				0			0				700
Series J Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)				300	300		300
Convertible Preferred Stock, Conversion Price1 (in dollars per share) | $ / shares	$ 2
Stock Issued During Period, Shares, New Issues (in shares)	300
Proceeds from Issuance of Preferred Stock and Preference Stock | $	$ 300,000
Stock Conversion, Conversion Price Trigger (in dollars per share) | $ / shares	$ 0.50
Percentage of Lower Volume Weighted Average Price of Common Stock	80.00%

Note 10 - Stockholders' Equit_3

Note 10 - Stockholders' Equity - Preferred Stock Summary (Details) - USD ($)	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019
Preferred stock, shares outstanding (in shares)	400		2,486
Preferred Stock	$ 376,095		$ 1,932,433
Series B Convertible Preferred Stock [Member]
Preferred stock, shares outstanding (in shares)	100		100
Preferred Stock	$ 76,095		$ 76,095
Series H Convertible Preferred Stock [Member]
Preferred stock, shares outstanding (in shares)	0		1,686
Preferred Stock			$ 1,156,338
Series I Convertible Preferred Stock [Member]
Preferred stock, shares outstanding (in shares)	0		700
Preferred Stock			$ 700,000
Series J Convertible Preferred Stock [Member]
Preferred stock, shares outstanding (in shares)	300	300
Preferred Stock	$ 300,000

Note 10 - Stockholders' Equit_4

Note 10 - Stockholders' Equity - Summary of Warrants (Details) - $ / shares	Jun. 30, 2020	Jun. 26, 2020	Jun. 20, 2020	Jan. 31, 2020
Series G Warrants [Member]
Exercise price (in dollars per share)	$ 0.50		$ 0.50	$ 25,440
Number of warrants (in shares)	48
Series H Warrants [Member]
Exercise price (in dollars per share)	$ 0.50		0.50	1.15
Number of warrants (in shares)	217,392
Series I Warrants [Member]
Exercise price (in dollars per share)	$ 0.50		$ 0.50	$ 15,000
Number of warrants (in shares)	1,500,000
June 2020 Warrants [Member]
Exercise price (in dollars per share)	$ 0.50	$ 0.50
Number of warrants (in shares)	2,400,000

Note 11 - Income Taxes (Details

Note 11 - Income Taxes (Details Textual) $ in Thousands	6 Months Ended
	Jun. 30, 2020USD ($)
Income Taxes Paid	$ 0

Note 12 - Grants and Collabor_2

Note 12 - Grants and Collaboration Revenue (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenue from Contract with Customer, Including Assessed Tax	$ 440,602	$ 209,941	$ 1,156,579	$ 574,173
Unused Grant Funds	650,051		650,051
NIH Grants [Member]
Revenue from Contract with Customer, Including Assessed Tax	301,493	184,938	955,514	539,257
Research Agreements [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 139,109	$ 25,003	$ 201,065	$ 34,916

Note 13 - Subsequent Events (De

Note 13 - Subsequent Events (Details Textual) - Subsequent Event [Member]	1 Months Ended
	Jul. 31, 2020shares
Series H and Series I Warrants [Member]
Class of Warrant or Right, Exercised During Period (in shares)	1,091,128
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	738,048
Conversion of Series J Preferred Stock To Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)	300
Conversion of Stock, Shares Issued (in shares)	854,458